Just to recap some of the information: NPAT at 0.9 millions for half year and Revenue at 15.6millions.
This represents a net profit margin of 5.7%, in comparison with 3% last year.
So, profit is about double the last year's figure. Revenue is only up 8%. With backlog order reduced to 3.8 millions from 6millions. Growth is strongest in Asia, 13%; in USA 6%, and Germany Business Unit 10%.
I am happy with the profit. The revenue is really looking good. Revenue still grows organically.
I don't think the sale backlog reduction has been fully translated into Revenue yet, because some order is probably invoiced but not yet paid (depending on the accounting approach in CMP's report).
Good points:
1. Improving profit margin (very good for me)
2. Continued organic growth in revenue
3. lower AUD
4. Coming news on eHealth ! (most exciting for me)
5. New market of LTEM
6. Cash flow is reduced, because more capital is used for increasing production. 2nd half should look strong, if not stronger
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)